List of Excipients in Branded Drug PARSABIV

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amgen Inc	PARSABIV	etelcalcetide	55513-740	HYDROCHLORIC ACID	2034-06-27
Amgen Inc	PARSABIV	etelcalcetide	55513-740	SODIUM CHLORIDE	2034-06-27
Amgen Inc	PARSABIV	etelcalcetide	55513-740	SODIUM HYDROXIDE	2034-06-27
Amgen Inc	PARSABIV	etelcalcetide	55513-740	SUCCINIC ACID	2034-06-27

Parsabiv Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Parsabiv, Amgen’s intravenous etelcalcetide product, uses a deliberately minimal excipient system: water for injection, with hydrochloric acid and sodium hydroxide available for pH adjustment. The formulation strategy prioritizes low excipient burden, dialysis-center handling, single-dose administration, and compatibility with intravenous use. Commercial opportunities are concentrated in manufacturing efficiency, ready-to-administer formats, container-closure systems, regional supply, and generic or follow-on development rather than in adding conventional formulation excipients.

What is Parsabiv and how is it administered?

Parsabiv contains etelcalcetide hydrochloride, an intravenous calcimimetic approved for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease who are receiving hemodialysis. The drug activates the calcium-sensing receptor on the parathyroid gland and reduces parathyroid hormone secretion.[1]

Attribute	Parsabiv profile
Active ingredient	Etelcalcetide hydrochloride
Brand owner	Amgen
FDA application	NDA 208325
Dosage form	Intravenous injection
Strengths	2.5 mg/0.5 mL, 5 mg/1 mL, 10 mg/2 mL
Administration	Intravenous, generally at the end of hemodialysis
Indication	Secondary hyperparathyroidism in adults with CKD receiving hemodialysis
FDA approval	February 7, 2017
Primary commercial channel	Dialysis providers, hospitals and specialty distributors

The product is supplied in single-dose vials. The dose is administered intravenously by dialysis-center personnel, which reduces the commercial value of patient-facing delivery features such as autoinjectors, oral absorption enhancers or home-use preservatives.

Parsabiv is not indicated for patients with CKD who are not receiving hemodialysis. The label requires monitoring of serum calcium and adjustment or interruption of treatment when clinically appropriate.[1]

What excipients are used in Parsabiv?

The Parsabiv formulation has one principal functional excipient: water for injection. Hydrochloric acid and sodium hydroxide may be used to adjust pH. The product does not rely on a conventional buffer system, antimicrobial preservative, surfactant or tonicity modifier listed as a routine inactive ingredient in the FDA labeling.[1]

Formulation element	Function	Commercial implication
Water for injection	Aqueous vehicle	Supports a simple, low-cost liquid formulation
Hydrochloric acid	pH adjustment	Enables final pH control during manufacture
Sodium hydroxide	pH adjustment	Enables final pH control during manufacture
Preservatives	Not listed as routine inactive ingredients	Supports single-dose vial positioning
Surfactants	Not listed as routine inactive ingredients	Reduces excipient complexity
Buffer salts	Not listed as routine inactive ingredients	Limits ionic load and formulation components

This excipient profile is strategically suitable for a parenteral product used in dialysis clinics. It reduces the number of raw materials requiring qualification and limits potential interactions with the active peptide.

The absence of a conventional preservative is consistent with the single-dose vial presentation. That choice avoids preservative exposure but places greater emphasis on aseptic manufacturing, container integrity and controlled-use procedures at the point of care.

Why does Parsabiv use a minimal excipient system?

Etelcalcetide is a peptide-based molecule with a complex structure that includes disulfide chemistry and a cysteine-containing component. A simple aqueous formulation can reduce the risk of incompatibility between the active ingredient and excipients that may affect aggregation, oxidation, adsorption or chemical degradation.

A minimal formulation also supports the product’s clinical workflow:

1. The vial is stored under refrigerated conditions.
2. The product is removed for use in the dialysis setting.
3. The prescribed volume is administered intravenously.
4. The container is discarded after single use.

The strategy avoids unnecessary formulation complexity in a product administered by trained professionals rather than by patients. This can reduce manufacturing steps, analytical testing requirements and raw-material qualification costs.

The trade-off is that the formulation has less tolerance for poor handling. Commercial value therefore shifts from excipient innovation to stability control, vial engineering, cold-chain execution and manufacturing consistency.

What are the key physical and chemical formulation issues?

Peptide stability

Peptide products can face aggregation, oxidation, deamidation, adsorption to manufacturing equipment or container surfaces, and sensitivity to temperature excursions. The Parsabiv formulation addresses these risks through product-specific manufacturing controls and refrigerated storage rather than through a broad excipient package.

The commercial importance of these controls is high because a dialysis provider may purchase multiple strengths and hold inventory across treatment locations. A supplier that improves shelf-life or excursion tolerance without changing the approved formulation could gain an advantage in procurement and distribution.

pH control

Hydrochloric acid and sodium hydroxide are used for pH adjustment rather than as a conventional buffer pair. This can simplify the formulation while preserving the required pH range. It also creates manufacturing sensitivity around bulk solution preparation, mixing order, hold time and final pH measurement.

A follow-on manufacturer would need to establish that its pH profile, impurity pattern and stability performance remain comparable to the reference product.

Container interaction

The product is supplied in glass vials. Peptide adsorption, extractables and leachables, siliconization, stopper compatibility and vial surface treatment can affect product quality. Container-closure selection is therefore a potential source of protectable formulation or packaging know-how even when the listed excipient composition is simple.

Temperature management

Parsabiv is stored in a refrigerator at 2°C to 8°C and should be protected from light. The label does not permit freezing.[1] Cold-chain requirements create a logistics cost but also create opportunities for improved packaging, validated excursion management and regional fill-finish capacity.

What commercial opportunities exist in Parsabiv excipients and formulation?

The strongest commercial opportunities are not likely to come from selling a new excipient into the branded product. They are more likely to arise from supplying critical materials, improving manufacturing performance or developing a follow-on product with a differentiated presentation.

1. Aseptic manufacturing and fill-finish

Parsabiv’s single-dose liquid-vial format is compatible with conventional sterile fill-finish infrastructure. Contract manufacturers can compete on:

• Low-volume peptide filling
• Aseptic processing
• Vial washing and sterilization
• Stopper and seal compatibility
• Inspection of clear or near-clear parenteral solutions
• Cold-chain release and distribution
• Small-batch production across three strengths

A supplier with validated experience in peptide injectables may reduce scale-up risk for a generic or regional entrant.

2. Container-closure systems

The vial and closure system can create a commercial niche for suppliers offering:

• Low-adsorption glass or coated containers
• Elastomeric stoppers with low extractables
• Improved seal integrity
• Light-protective secondary packaging
• Automated single-dose handling
• Compatibility with dialysis-center storage conditions

These improvements may support a regulatory filing if they change the container-closure system. They may also be used as manufacturing advantages without creating a separately marketed formulation product.

3. Ready-to-administer presentations

A prefilled syringe, cartridge or dialysis-compatible dose format could reduce preparation steps. The opportunity is constrained by the product’s intravenous administration, dose variability and need for health-care professional control.

A ready-to-administer format would need to address:

• Peptide stability in the delivery device
• Syringe and needle adsorption
• Silicone oil exposure
• Container-closure integrity
• Dose flexibility across 2.5 mg, 5 mg and 10 mg strengths
• Compatibility with dialysis-unit procedures
• Demonstration of equivalent safety and performance

The commercial proposition would be workflow reduction rather than improved patient adherence.

4. Stability-enhanced formulations

A modified formulation could target one or more of the following:

• Longer room-temperature stability
• Greater resistance to temperature excursions
• Reduced aggregation
• Lower surface adsorption
• Improved compatibility with alternate primary containers
• Longer in-use time after vial entry

Potential excipient classes include stabilizing amino acids, sugars, polyols, surfactants or buffering agents. Each addition would create a new regulatory and analytical burden. The commercial value would depend on whether the change solves a measurable dialysis-provider problem.

5. Regional manufacturing

Because Parsabiv is used in institutional settings, local or regional production may improve supply resilience and reduce cold-chain distance. Opportunities exist in markets where dialysis networks prefer local sourcing or where import logistics increase inventory costs.

The main barriers are peptide synthesis, sterile processing, analytical characterization, validated cold storage and regulatory comparability. A simple excipient system does not eliminate those barriers.

What formulation patents could protect Parsabiv or a follow-on product?

Patent protection can cover more than the listed excipients. Relevant claim categories may include:

Claim category	Potential subject matter
Composition of matter	Etelcalcetide chemical structure, salts or related peptide forms
Pharmaceutical composition	Etelcalcetide with specified concentration, pH, purity or excipient range
Manufacturing	Peptide synthesis, disulfide formation, purification and impurity control
Stability	Conditions or compositions that limit aggregation or degradation
Container system	Vial, stopper, coating or packaging configuration
Method of use	Treatment of secondary hyperparathyroidism in hemodialysis patients
Dosing	Administration timing, dose titration or calcium-management protocols

The listed excipient profile does not establish the scope of Amgen’s patent estate. Patent claims must be reviewed in the United States Patent and Trademark Office records, FDA Orange Book listings and relevant national registers. Orange Book entries may cover drug substance, drug product or method-of-use claims, but the Orange Book does not provide a complete record of every manufacturing, formulation or foreign patent.

A generic sponsor should separate three issues:

1. Whether an active-ingredient patent remains enforceable.
2. Whether an Orange Book-listed drug-product or method-of-use patent applies to the proposed label.
3. Whether non-Orange Book process, formulation or packaging patents create commercial litigation risk.

When does Parsabiv lose exclusivity?

FDA approval in 2017 established the regulatory starting point, but the actual generic-entry date depends on statutory exclusivity, patent terms, pediatric extensions, litigation and any settlement arrangements.

For a small-molecule-like peptide product, a follow-on sponsor may evaluate an abbreviated pathway only if FDA determines that the relevant product qualifies for an ANDA. If the product’s molecular complexity, analytical requirements or formulation differences prevent an ANDA, a 505(b)(2) application may be considered. The appropriate pathway depends on FDA’s product-specific determination.

Key exclusivity considerations include:

Exclusivity issue	Relevance to Parsabiv
New chemical entity exclusivity	Must be checked against the approved NDA and FDA exclusivity records
Three-year exclusivity	Could affect certain follow-on approvals based on new clinical investigations
Pediatric exclusivity	Can add six months if granted
Patent listing	Relevant to Paragraph IV certifications
Patent litigation	A timely suit can trigger a 30-month stay under the Hatch-Waxman framework
Settlement agreements	May establish an agreed generic-entry date
Regulatory exclusivity outside the U.S.	Varies by jurisdiction

A precise loss-of-exclusivity date requires a current Orange Book and FDA exclusivity review. The approval date alone does not establish the first lawful generic launch date.

Are there Paragraph IV challenges to Parsabiv?

A Paragraph IV challenge would require a generic applicant to certify that an Orange Book-listed patent is invalid, unenforceable or not infringed. Public assessment should include:

• Current FDA Orange Book patent listings for NDA 208325
• ANDA applicants identified in FDA litigation or approval records
• Federal court docket searches involving Amgen and etelcalcetide
• Paragraph IV notice letters where publicly disclosed
• Any 30-month stay associated with a listed patent
• Settlement terms and agreed entry dates

The commercial risk is different from ordinary tablet generics. Etelcalcetide is a peptide injection used in a controlled clinical setting, so FDA review may focus heavily on molecular characterization, impurities, potency, aggregation, sterility and container compatibility.

How strong is the Parsabiv patent estate?

The estate’s practical strength depends on claim breadth and the ability to prove infringement. Composition-of-matter claims generally create the strongest barrier if they remain enforceable and cover the active ingredient used by a follow-on product.

Formulation claims are more vulnerable when a competitor can use a different excipient system, pH range, concentration or container. Method-of-use claims may be avoidable if a generic label omits patented dosing instructions, although induced-infringement and label-scrubbing issues can complicate that analysis.

Manufacturing claims may remain commercially relevant even when a competitor avoids composition claims. Their value depends on whether the patented process is necessary for efficient production or whether an alternative synthetic route is practical.

For Parsabiv, the minimal excipient composition may limit the number of conventional formulation barriers. The stronger commercial defenses are likely to be active-ingredient claims, process controls, peptide impurity specifications, regulatory complexity and dialysis-provider contracting.

How does Parsabiv compare with Sensipar and generic cinacalcet?

Factor	Parsabiv	Sensipar/cinacalcet
Active ingredient	Etelcalcetide	Cinacalcet
Route	Intravenous	Oral
Treatment setting	Hemodialysis center	Patient-administered oral therapy
Formulation	Aqueous single-dose vial	Solid oral dosage forms
Excipient strategy	Minimal parenteral system	Tablet excipient system
Adherence control	Administered by dialysis personnel	Depends on patient adherence
Generic complexity	Peptide injectable and sterile product	Conventional oral generic pathway
Commercial differentiation	Workflow, dosing control and dialysis integration	Oral convenience and price
Cold chain	Required	Generally less demanding

Parsabiv’s main commercial advantage is administration during dialysis, which can reduce reliance on patient adherence. Cinacalcet’s advantage is oral convenience and a broader generic manufacturing base. A low-cost cinacalcet generic can pressure Parsabiv pricing, while Parsabiv can retain value in patients for whom supervised intravenous treatment is clinically or operationally attractive.

What revenue and market opportunities exist for Parsabiv?

Parsabiv’s addressable market is tied to the global hemodialysis population and treatment of secondary hyperparathyroidism. The product is not a broad CKD therapy. Its use depends on dialysis-center protocols, nephrologist preference, reimbursement, serum calcium management and availability of oral calcimimetics.

Commercial opportunities include:

• Preferred-product contracts with dialysis networks
• Bundled procurement with dialysis medications
• Regional cold-chain distribution
• Hospital and outpatient dialysis formulary placement
• Contract manufacturing of etelcalcetide injection
• Follow-on products with lower acquisition cost
• Device-based presentations that reduce preparation time
• Supply agreements for critical sterile components
• Geographic expansion in markets with growing dialysis capacity

Revenue exposure is concentrated in institutional purchasing rather than retail pharmacy demand. A competitor would need to demonstrate not only regulatory equivalence but also reliable supply across dialysis networks. Stockouts, strength-specific shortages or vial wastage can influence formulary decisions.

What generic launch scenarios exist for Parsabiv?

Scenario 1: Conventional generic injection

A sponsor develops the same strengths, route, dosage form and excipient profile. This approach minimizes clinical differentiation but requires strong analytical comparability and sterile manufacturing capability.

Scenario 2: 505(b)(2) formulation

A sponsor develops a materially different excipient system, container or presentation. The pathway may support a differentiated product but could require additional clinical or bridging data.

Scenario 3: Regional licensed product

A manufacturer licenses etelcalcetide technology or supplies a local product under a regional regulatory pathway. This can reduce development time but creates dependence on patent clearance and technology-transfer execution.

Scenario 4: Workflow-focused presentation

A sponsor markets a prefilled or dialysis-compatible presentation. The product could command a premium if it reduces preparation labor, dosing errors or waste. Device compatibility and stability would be central development risks.

Scenario 5: Process-led price competition

A manufacturer uses a lower-cost peptide synthesis and purification process while retaining a reference-like formulation. This scenario offers the clearest route to a lower acquisition cost but may face manufacturing patent and impurity-profile challenges.

Key Takeaways

• Parsabiv uses a minimal aqueous formulation based principally on water for injection, with hydrochloric acid and sodium hydroxide used for pH adjustment.
• The single-dose vial and intravenous dialysis-center administration reduce the need for preservatives, buffers and patient-oriented delivery excipients.
• The principal formulation opportunities are stability improvement, container-closure engineering, ready-to-administer presentations and fill-finish efficiency.
• Generic competition is more complex than ordinary oral solid-dose competition because etelcalcetide is a peptide injectable requiring sterile manufacturing and extensive analytical characterization.
• Active-ingredient, process, formulation, container and method-of-use patents must be assessed separately.
• The commercial market is concentrated in dialysis-provider procurement, where supply reliability and workflow integration may be as important as unit price.
• A current Orange Book, FDA exclusivity and court-docket review is required to establish the actual generic-entry date and Paragraph IV exposure.

FAQs About Parsabiv Excipient and Commercial Strategy

Does Parsabiv contain a preservative?

The FDA label identifies water for injection as the inactive ingredient and permits hydrochloric acid or sodium hydroxide for pH adjustment. A conventional preservative is not listed.[1]

Can Parsabiv be reformulated as a prefilled syringe?

A prefilled syringe is technically possible but would require assessment of peptide adsorption, stability, extractables and leachables, container-closure integrity, dose flexibility and FDA regulatory requirements.

Is etelcalcetide a biologic?

Etelcalcetide is a peptide-based drug administered by injection. Its regulatory treatment depends on the applicable FDA product pathway and product-specific classification; it should not be assumed to follow the same pathway as a monoclonal antibody biosimilar.

What is the main manufacturing barrier for a Parsabiv generic?

The main barriers are peptide synthesis and purification, disulfide-related impurity control, sterile liquid fill-finish, molecular comparability, container compatibility and cold-chain stability.

Can a new excipient create a separate Parsabiv product opportunity?

Yes, if the excipient improves stability, handling or delivery and the sponsor can support the product through the applicable FDA pathway. The commercial value depends on whether the improvement reduces dialysis-center labor, waste, storage risk or supply cost.

References

1. U.S. Food and Drug Administration. (2024). Parsabiv (etelcalcetide) injection prescribing information. Amgen Inc.
2. U.S. Food and Drug Administration. (2017). FDA approves Parsabiv for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Amgen Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database, NDA 208325.